No headlines found.
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
Globe Newswire (Wed, 27-Mar 8:00 AM ET)
Globe Newswire (Mon, 25-Mar 8:00 AM ET)
Globe Newswire (Mon, 11-Mar 7:00 AM ET)
Globe Newswire (Tue, 5-Mar 4:05 PM ET)
Globe Newswire (Tue, 27-Feb 8:00 AM ET)
Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focuses on the discovery, development, and delivery of complex treatments for patients battling cancer and rare diseases. Its product pipeline includes Patented RNL and Patented DocePLUS.
Plus Therapeutics trades on the NASDAQ stock market under the symbol PSTV.
As of March 28, 2024, PSTV stock price declined to $1.80 with 41,383 million shares trading.
PSTV has a beta of 3.42, meaning it tends to be more sensitive to market movements. PSTV has a correlation of 0.09 to the broad based SPY ETF.
PSTV has a market cap of $5.20 million. This is considered a Sub-Micro Cap stock.
Last quarter Plus Therapeutics reported $1 million in Revenue and -$.70 earnings per share. This beat revenue expectation by $253,000 and exceeded earnings estimates by $.37.
In the last 3 years, PSTV stock traded as high as $53.10 and as low as $.97.
The top ETF exchange traded funds that PSTV belongs to (by Net Assets): VXF.
PSTV has underperformed the market in the last year with a return of -56.2%, while the SPY ETF gained +33.6%. In the last 3 month period, PSTV fell short of the market, returning -1.9%, while SPY returned +10.1%. However, in the most recent 2 weeks PSTV has outperformed the stock market by returning +2.0%, while SPY returned +1.7%.
PSTV support price is $1.75 and resistance is $1.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PSTV stock will trade within this expected range on the day.